TC TTOO MALL ROOM



ATTORNEY DOCKET NO.: 2002645-0003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ensley, et al.

Examiner:

Serial No.:

09/659,926

Art Unit:

Filing Date:

September 12, 2000

Title:

NUTRITIONAL SUPPLEMENTS CONTAINING

METHYLSELENOCYSTEINE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

TRANSMITTAL

Enclosed please find the following documents regarding the above-referenced matter:

- 1. Request for Correction of Filing Receipt (2 pgs);
- 2. Copy of Filing Receipt (3pg); and
- 3. Return Postcard.

Please charge any fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully Submitted,

Brenda Herschbach Jarrell, Ph.D. Registration Number: 39,223

ATTORNEYS FOR APPLICANT Choate, Hall & Stewart Exchange Place 53 State Street Boston, MA 02109

Phone: (617) 248-5000 Fax: (617) 248-4000

Email: bjarrell@choate.com Dated: December 4, 2000

3199139_1.DOC

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231

n_____

Jaun Melsen



ATTORNEY'S DOCKET NO. 2002645-0003 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE The stall and the state of the state

Applicant:

Serial No.:

Filing Date:

Title:

METHYLSELENOCYSTEINE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

REQUEST FOR CORRECTION OF FILING RECEIPT

Applicant respectfully requests correction of the following errors in the filing receipt (copy attached) for the above-referenced case:

- 1. The attorney name and address is incorrect. The correct attorney name is Brenda Herschbach Jarrell. The correct address is Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109.
- 2. The residence for Cynthia Orser is McLean, VA.
- 3. The number of independent claims is incorrect. The correct number of independent claims should be eight (8). Accordingly, the proper filing fee for this application should have been \$822.00. Please charge any fees or credit any overpayments to our Deposit Account No. 03-1721.
- 5. In the title, "methyselenocysteine" is incorrectly spelled. The correct spelling is "methylselenocysteine".

I hereby certury that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231



Applicant respectfully requests that a corrected filing receipt be issued as soon as possible.

Respectfully submitted,

Brenda Herschbach Jarrell, Ph.D. Reg. No.: 39,223

ATTORNEYS FOR APPLICANT Choate, Hall & Stewart **Exchange Place** 53 State Street Boston, MA 02109 Tel. No. (617) 248-5000


Fax No.: (617) 248-4000 Email: bjarrell@choate.com Date: December 4, 2000

3197255_1.DOC

TC 1700 MAIL ROOM



United States Patent and Trademark Office



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.uspto.gov

	FILING DATE	CRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
APPLICATION NUMBER	FILING DATE	GRI ART GILL	<u></u>	2002645-	6	48	7
09/659.926	09/12/2000	1761	0	0003	O	,0	

FILING RECEIPT

OC00000005550049

Brenda Herschbach Jarrell Choate Hall & Stewart Exchange Place 53 State Street Boston, MA 02109

Date Mailed: 11/13/2000

TC 1700 MAIL ROOM

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any noted thereon.

Applicant(s)

Burt D. Ensley, Newton, PA; David Salt, Highland Park, NJ; Cynthia Orser, Residence Not Provided;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/041,355 03/12/1998 PAT 6,117,462

Foreign Applications

If Required, Foreign Filing License Granted 11/13/2000

** SMALL ENTITY **

Title

Nutritional supplements containing methyselenocysteine

Preliminary Class

426

Data entry by : MOLLISH, CHRISTINE

Team : OIPE

Date: 11/13/2000

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

11/12/00